Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NateraMEX:NTRA 60 Days Payable is 17.73 as of Mar. 2026, which is 19% below its 10-year median of 21.79. GuruFocus rates MEX:NTRA with a GF Score™ of 60/100 and a GF Value™ of MXN2,983.49 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Natera ranks worse than 90.53% on this metric.
Natera's average Accounts Payable for the
three
months ended in Mar. 2026 was MXN861 Mil. Natera's Cost of Goods Sold for the
three
months ended in Mar. 2026 was MXN4,433 Mil.
Hence, Natera's Days Payable for the
three
months ended in Mar. 2026 was 17.73.
The historical rank and industry rank for Natera's Days Payable or its related term are showing as below:
MEX:NTRA'
s Days Payable Range Over the Past 10 Years
Min: 13.52 Med: 21.79 Max: 26.16
Current: 18.23
During the past 13 years, Natera's highest Days Payable was 26.16. The lowest was 13.52. And the median was 21.79.
MEX:NTRA's Days Payable is ranked worse than 90.53% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.64
vs MEX:NTRA: 18.23
Natera's Days Payable
declined
from Mar. 2025 (18.45) to Mar. 2026 (17.73).
It may suggest that Nateraaccelerated paying its suppliers.
Natera Days Payable Related Terms
Natera Days Payable Historical Data
* Premium members only.
The historical data trend for Natera's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Natera's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natera Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Natera's Days Payable distribution charts can be found below:
* The bar in red indicates where Natera's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Natera's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Natera (MEX:NTRA) has a Days Payable of 17.73 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Natera and its competitors. This is 19% below median its historical median of 21.79. Over the past decade, Natera's Days Payable has ranged from 13.52 to 26.16. According to the industry distribution chart, Natera ranks #172 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 90.5%.
Is Natera's Days Payable too high?
Natera's current Days Payable of 17.73 is 19% below median its 10-year median of 21.79. Over the past 10 years, this metric has ranged from a low of 13.52 to a high of 26.16. The Medical Diagnostics & Research industry median Days Payable is 64.64. Natera's value of 17.73 is 72.6% below this industry median. Based on the distribution chart, Natera ranks #172 out of 190 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Natera has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Natera's Days Payable compare to WAT and A?
According to the Medical Diagnostics & Research industry distribution chart, Natera ranks #172 out of 190 companies for Days Payable. This places Natera in the lower half of its industry. The industry median Days Payable is 64.64. Natera's value of 17.73 is 72.6% below this benchmark. Historically, Natera's own Days Payable has ranged from 13.52 to 26.16 over the past decade. While the company's 10-year median is 21.79 vs. the industry median of 64.64, Natera has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Natera's current Days Payable of 17.73 is 72.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Natera and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Natera's current Days Payable is 17.73, which is 19% below median its own 10-year median of 21.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natera stock overvalued right now?
Based on GuruFocus' analysis, Natera (MEX:NTRA) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN2,983.49, compared to a current price of MXN3,905.00 — trading 30.9% above its estimated fair value. The current Days Payable is 17.73, which is 19% below median its 10-year median of 21.79 and 72.6% below the Medical Diagnostics & Research industry median of 64.64. Natera's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Natera (MEX:NTRA), the current Days Payable is 17.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Natera (MEX:NTRA) Overvalued in 2026?
Based on GuruFocus' analysis, Natera stock appears to be overvalued.
The current stock price of MXN3,905.00 is trading 30.9% above its estimated GF Value™ of MXN2,983.49.
GuruFocus considers Natera to be Significantly Overvalued.
Key valuation signals for MEX:NTRA:
Days Payable: 17.73 (19% below median its 10-year median of 21.79)
GF Value™: MXN2,983.49 vs. price of MXN3,905.00 (30.9% above fair value)
Industry Position: 72.6% below the Medical Diagnostics & Research median (#172 of 190)
No single metric tells the full story. See the MEX:NTRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
60GF Score
Get the complete analysis for MEX:NTRA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NTRA has been successfully added to your 
